Trending

Lantus

Sanofi builds case for Toujeo in younger type 1 diabetics

Sanofi builds case for Toujeo in younger type 1 diabetics

Sanofi’s Toujeo – a follow-up to its long-acting insulin drug Lantus – has underperformed commercially since launch but

X

Sanofi builds case for Toujeo in younger type 1 diabetics

https://pharmaphorum.com/news/sanofi-builds-case-for-toujeo-in-younger-type-1-diabetics/

Mylan’s Lantus biosimilar held up by manufacturing issue

Mylan’s Lantus biosimilar held up by manufacturing issue

Mylan’s hopes of grabbing a slice of the big US market for insulin glargine – the active ingredient

X

Mylan’s Lantus biosimilar held up by manufacturing issue

https://pharmaphorum.com/news/mylans-lantus-biosimilar-held-up-by-manufacturing-issue/

Sanofi beats expectations, driven by rare diseases and vaccines

Sanofi beats expectations, driven by rare diseases and vaccines

But sales of key insulin fall amid biosimilar competition.

X

Sanofi beats expectations, driven by rare diseases and vaccines

https://pharmaphorum.com/news/sanofi-beats-expectations-driven-rare-diseases-vaccines/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com